| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 78 | 2025 | 532 | 16.200 |
Why?
|
| Erectile Dysfunction | 38 | 2025 | 180 | 13.630 |
Why?
|
| Hypogonadism | 51 | 2024 | 281 | 13.290 |
Why?
|
| Hormone Replacement Therapy | 37 | 2025 | 195 | 8.550 |
Why?
|
| Prostatic Neoplasms | 33 | 2025 | 1525 | 6.010 |
Why?
|
| Penile Prosthesis | 11 | 2024 | 33 | 4.340 |
Why?
|
| Androgens | 17 | 2021 | 274 | 4.290 |
Why?
|
| Penile Implantation | 8 | 2024 | 20 | 3.880 |
Why?
|
| Prostatectomy | 20 | 2022 | 332 | 2.850 |
Why?
|
| Prostate-Specific Antigen | 13 | 2025 | 256 | 2.430 |
Why?
|
| Penile Induration | 5 | 2024 | 31 | 2.410 |
Why?
|
| Penile Erection | 16 | 2023 | 74 | 2.410 |
Why?
|
| Cardiovascular Diseases | 20 | 2025 | 1877 | 2.330 |
Why?
|
| Male | 132 | 2025 | 60345 | 2.210 |
Why?
|
| Sexual Dysfunction, Physiological | 7 | 2024 | 79 | 1.700 |
Why?
|
| Libido | 5 | 2022 | 34 | 1.680 |
Why?
|
| Patient Satisfaction | 9 | 2025 | 476 | 1.610 |
Why?
|
| Stem Cell Transplantation | 3 | 2024 | 238 | 1.590 |
Why?
|
| Penis | 10 | 2025 | 97 | 1.500 |
Why?
|
| Humans | 136 | 2025 | 123280 | 1.490 |
Why?
|
| Urology | 4 | 2024 | 74 | 1.400 |
Why?
|
| Sexual Behavior | 9 | 2024 | 243 | 1.270 |
Why?
|
| Depression | 5 | 2018 | 1229 | 1.080 |
Why?
|
| Aged | 43 | 2025 | 19180 | 1.020 |
Why?
|
| Middle Aged | 48 | 2025 | 26095 | 0.970 |
Why?
|
| Holistic Health | 1 | 2025 | 11 | 0.960 |
Why?
|
| Finasteride | 2 | 2022 | 20 | 0.950 |
Why?
|
| Platelet-Rich Plasma | 1 | 2024 | 15 | 0.940 |
Why?
|
| Microbial Collagenase | 1 | 2024 | 12 | 0.940 |
Why?
|
| Watchful Waiting | 1 | 2025 | 68 | 0.940 |
Why?
|
| Sexual Health | 1 | 2024 | 9 | 0.900 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 20 | 0.890 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2025 | 106 | 0.880 |
Why?
|
| Androgen Antagonists | 2 | 2024 | 118 | 0.880 |
Why?
|
| Health Care Costs | 3 | 2018 | 366 | 0.880 |
Why?
|
| Reproductive Health | 1 | 2024 | 44 | 0.860 |
Why?
|
| Prosthesis Design | 4 | 2024 | 675 | 0.790 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2021 | 4 | 0.780 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2021 | 30 | 0.770 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 269 | 0.750 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2021 | 13 | 0.750 |
Why?
|
| Surveys and Questionnaires | 12 | 2025 | 3678 | 0.740 |
Why?
|
| Cystic Fibrosis | 1 | 2024 | 257 | 0.730 |
Why?
|
| Telemedicine | 2 | 2024 | 426 | 0.710 |
Why?
|
| Polycythemia | 1 | 2020 | 42 | 0.700 |
Why?
|
| Treatment Outcome | 23 | 2024 | 12176 | 0.690 |
Why?
|
| Eunuchism | 2 | 2022 | 7 | 0.680 |
Why?
|
| Retrospective Studies | 23 | 2025 | 16081 | 0.670 |
Why?
|
| Adult | 33 | 2025 | 29091 | 0.650 |
Why?
|
| Curriculum | 1 | 2024 | 716 | 0.640 |
Why?
|
| Fertility | 2 | 2018 | 263 | 0.630 |
Why?
|
| Prostate | 4 | 2023 | 431 | 0.620 |
Why?
|
| Clomiphene | 1 | 2018 | 12 | 0.620 |
Why?
|
| North America | 7 | 2024 | 239 | 0.620 |
Why?
|
| Spinal Cord Injuries | 3 | 2007 | 310 | 0.600 |
Why?
|
| Botulinum Toxins, Type A | 3 | 2005 | 167 | 0.590 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2017 | 60 | 0.570 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 76 | 0.560 |
Why?
|
| Societies, Medical | 5 | 2024 | 677 | 0.560 |
Why?
|
| Varicocele | 4 | 2010 | 54 | 0.540 |
Why?
|
| Quality of Life | 7 | 2024 | 1934 | 0.530 |
Why?
|
| Prospective Studies | 12 | 2025 | 6033 | 0.520 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 254 | 0.510 |
Why?
|
| Abdominal Wall | 1 | 2015 | 32 | 0.490 |
Why?
|
| Postoperative Complications | 7 | 2024 | 3019 | 0.490 |
Why?
|
| Impotence, Vasculogenic | 2 | 2014 | 10 | 0.470 |
Why?
|
| Comorbidity | 7 | 2018 | 1497 | 0.470 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 80 | 0.460 |
Why?
|
| Men's Health | 3 | 2024 | 19 | 0.460 |
Why?
|
| Drug Implants | 5 | 2015 | 42 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 1081 | 0.450 |
Why?
|
| United States | 18 | 2023 | 10655 | 0.440 |
Why?
|
| Prostatic Hyperplasia | 3 | 2023 | 113 | 0.440 |
Why?
|
| Urinary Bladder | 2 | 2005 | 242 | 0.440 |
Why?
|
| Medication Adherence | 1 | 2018 | 389 | 0.430 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2013 | 41 | 0.430 |
Why?
|
| Pandemics | 1 | 2021 | 1100 | 0.430 |
Why?
|
| Extracorporeal Shockwave Therapy | 2 | 2024 | 6 | 0.420 |
Why?
|
| Registries | 9 | 2018 | 1398 | 0.410 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 24 | 0.410 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 419 | 0.400 |
Why?
|
| Carcinoma | 1 | 2015 | 278 | 0.400 |
Why?
|
| Urologic Diseases | 2 | 2023 | 44 | 0.390 |
Why?
|
| Brachytherapy | 1 | 2012 | 74 | 0.380 |
Why?
|
| Klinefelter Syndrome | 1 | 2011 | 16 | 0.380 |
Why?
|
| Aging | 2 | 2016 | 1185 | 0.370 |
Why?
|
| Deficiency Diseases | 1 | 2011 | 11 | 0.370 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 52 | 0.370 |
Why?
|
| Heart Diseases | 1 | 2016 | 481 | 0.370 |
Why?
|
| Coitus | 2 | 2025 | 20 | 0.360 |
Why?
|
| Patient Compliance | 2 | 2011 | 469 | 0.350 |
Why?
|
| Risk Factors | 12 | 2021 | 10033 | 0.350 |
Why?
|
| Public Health | 1 | 2012 | 260 | 0.350 |
Why?
|
| Nitric Oxide | 1 | 2013 | 448 | 0.340 |
Why?
|
| Aged, 80 and over | 12 | 2023 | 6390 | 0.340 |
Why?
|
| Prevalence | 4 | 2018 | 2409 | 0.340 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 342 | 0.330 |
Why?
|
| Medicare | 5 | 2023 | 422 | 0.320 |
Why?
|
| Cardiovascular System | 3 | 2021 | 101 | 0.320 |
Why?
|
| Mass Screening | 1 | 2015 | 779 | 0.320 |
Why?
|
| Urologic Surgical Procedures, Male | 3 | 2019 | 38 | 0.320 |
Why?
|
| Estradiol | 4 | 2021 | 544 | 0.320 |
Why?
|
| Disease Progression | 3 | 2025 | 2031 | 0.300 |
Why?
|
| Administration, Oral | 3 | 2025 | 671 | 0.300 |
Why?
|
| Operative Time | 3 | 2018 | 159 | 0.290 |
Why?
|
| Gels | 4 | 2023 | 68 | 0.280 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2015 | 1218 | 0.280 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2297 | 0.280 |
Why?
|
| Receptors, Epoprostenol | 1 | 2007 | 14 | 0.280 |
Why?
|
| Databases, Factual | 3 | 2023 | 1170 | 0.280 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2007 | 28 | 0.270 |
Why?
|
| Linear Models | 3 | 2013 | 669 | 0.270 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2007 | 45 | 0.270 |
Why?
|
| Behavior Therapy | 2 | 2023 | 255 | 0.270 |
Why?
|
| Incidence | 5 | 2021 | 3055 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 716 | 0.260 |
Why?
|
| Urinary Incontinence | 1 | 2006 | 70 | 0.250 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 266 | 0.250 |
Why?
|
| Sensation | 1 | 2005 | 58 | 0.240 |
Why?
|
| Neurotoxins | 1 | 2005 | 56 | 0.240 |
Why?
|
| Mice, Nude | 2 | 2017 | 696 | 0.240 |
Why?
|
| Sexology | 1 | 2024 | 3 | 0.240 |
Why?
|
| Network Meta-Analysis | 1 | 2024 | 29 | 0.240 |
Why?
|
| Urethral Stricture | 1 | 2004 | 13 | 0.240 |
Why?
|
| Spermatogenesis | 2 | 2018 | 171 | 0.240 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 3286 | 0.240 |
Why?
|
| Injections, Intralesional | 1 | 2024 | 46 | 0.230 |
Why?
|
| Rats | 6 | 2020 | 3668 | 0.230 |
Why?
|
| Animals | 11 | 2023 | 33853 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1237 | 0.230 |
Why?
|
| Female | 12 | 2024 | 65629 | 0.230 |
Why?
|
| Cosmetic Techniques | 1 | 2024 | 11 | 0.230 |
Why?
|
| Blood Pressure | 3 | 2021 | 1327 | 0.230 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 44 | 0.220 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 286 | 0.220 |
Why?
|
| Health Expenditures | 2 | 2016 | 103 | 0.220 |
Why?
|
| Urinary Retention | 1 | 2023 | 18 | 0.220 |
Why?
|
| Neuromuscular Agents | 1 | 2004 | 67 | 0.220 |
Why?
|
| Alprostadil | 2 | 2016 | 27 | 0.220 |
Why?
|
| Patient Preference | 1 | 2025 | 115 | 0.220 |
Why?
|
| Bayes Theorem | 1 | 2024 | 279 | 0.220 |
Why?
|
| Neurocognitive Disorders | 1 | 2024 | 67 | 0.210 |
Why?
|
| Time Factors | 4 | 2024 | 6223 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 1251 | 0.210 |
Why?
|
| Receptors, Androgen | 3 | 2014 | 412 | 0.200 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 726 | 0.200 |
Why?
|
| Priapism | 1 | 2022 | 10 | 0.200 |
Why?
|
| Sildenafil Citrate | 2 | 2013 | 51 | 0.200 |
Why?
|
| Insurance Coverage | 1 | 2023 | 121 | 0.200 |
Why?
|
| Life Style | 1 | 2025 | 406 | 0.200 |
Why?
|
| Biopsy | 1 | 2025 | 1236 | 0.190 |
Why?
|
| Young Adult | 8 | 2021 | 8870 | 0.180 |
Why?
|
| Orchiectomy | 2 | 2017 | 49 | 0.170 |
Why?
|
| Azoospermia | 2 | 2010 | 39 | 0.170 |
Why?
|
| Traction | 1 | 2019 | 9 | 0.170 |
Why?
|
| Placenta | 1 | 2023 | 491 | 0.170 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2016 | 21 | 0.160 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 30 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2019 | 235 | 0.160 |
Why?
|
| Lipids | 3 | 2023 | 513 | 0.150 |
Why?
|
| Dementia | 1 | 2024 | 448 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 136 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 334 | 0.150 |
Why?
|
| Reoperation | 1 | 2021 | 819 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2020 | 162 | 0.150 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 65 | 0.150 |
Why?
|
| Hematocrit | 2 | 2021 | 112 | 0.150 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 103 | 0.150 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2014 | 38 | 0.150 |
Why?
|
| Chorionic Gonadotropin | 1 | 2018 | 86 | 0.150 |
Why?
|
| Double-Blind Method | 3 | 2023 | 1602 | 0.150 |
Why?
|
| Health Status | 2 | 2010 | 375 | 0.150 |
Why?
|
| Caffeine | 1 | 2018 | 71 | 0.140 |
Why?
|
| Exercise | 1 | 2023 | 814 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1440 | 0.140 |
Why?
|
| Recovery of Function | 4 | 2022 | 437 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2017 | 230 | 0.140 |
Why?
|
| Diabetes Complications | 2 | 2015 | 196 | 0.130 |
Why?
|
| Gene Expression | 1 | 2021 | 1567 | 0.130 |
Why?
|
| Dosage Forms | 1 | 2016 | 9 | 0.130 |
Why?
|
| Administration, Cutaneous | 2 | 2013 | 65 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 265 | 0.130 |
Why?
|
| Thrombosis | 1 | 2021 | 518 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2020 | 4692 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 5061 | 0.130 |
Why?
|
| Fasciotomy | 1 | 2015 | 27 | 0.130 |
Why?
|
| Personal Satisfaction | 2 | 2013 | 102 | 0.120 |
Why?
|
| Age Distribution | 1 | 2016 | 410 | 0.120 |
Why?
|
| Endothelium, Vascular | 2 | 2017 | 516 | 0.120 |
Why?
|
| Heterografts | 1 | 2015 | 178 | 0.120 |
Why?
|
| Heart Rate | 1 | 2017 | 588 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 142 | 0.120 |
Why?
|
| Biomarkers | 2 | 2015 | 2955 | 0.120 |
Why?
|
| Vulvodynia | 1 | 2014 | 3 | 0.120 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 31 | 0.120 |
Why?
|
| Luteinizing Hormone | 4 | 2015 | 132 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 502 | 0.120 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 22 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 884 | 0.120 |
Why?
|
| Endocrinology | 1 | 2017 | 141 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2015 | 269 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3236 | 0.110 |
Why?
|
| Nanostructures | 1 | 2014 | 52 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2015 | 381 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2015 | 116 | 0.110 |
Why?
|
| Reproduction | 1 | 2016 | 243 | 0.110 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2013 | 27 | 0.110 |
Why?
|
| Postoperative Period | 3 | 2022 | 333 | 0.110 |
Why?
|
| Bone Density | 1 | 2016 | 316 | 0.110 |
Why?
|
| Infertility, Male | 2 | 2015 | 264 | 0.110 |
Why?
|
| Streptozocin | 1 | 2013 | 24 | 0.110 |
Why?
|
| Nitric Oxide Synthase | 2 | 2016 | 187 | 0.110 |
Why?
|
| Microspheres | 1 | 2013 | 70 | 0.110 |
Why?
|
| Adolescent | 5 | 2022 | 19126 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 516 | 0.110 |
Why?
|
| Sulfones | 1 | 2013 | 66 | 0.110 |
Why?
|
| Body Composition | 1 | 2016 | 516 | 0.110 |
Why?
|
| Decision Making | 1 | 2018 | 652 | 0.100 |
Why?
|
| Purines | 1 | 2013 | 108 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 138 | 0.100 |
Why?
|
| Health Surveys | 2 | 2011 | 243 | 0.100 |
Why?
|
| Pregnancy | 2 | 2023 | 7129 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2014 | 164 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2021 | 3341 | 0.100 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 135 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 220 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2016 | 1389 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 424 | 0.100 |
Why?
|
| Tadalafil | 1 | 2011 | 4 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 228 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2013 | 303 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 807 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 1 | 2013 | 177 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 715 | 0.090 |
Why?
|
| Muscle Contraction | 2 | 2016 | 186 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2016 | 644 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 157 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1012 | 0.090 |
Why?
|
| Sexual Partners | 1 | 2011 | 85 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2005 | 1171 | 0.090 |
Why?
|
| Logistic Models | 2 | 2018 | 1799 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2018 | 1550 | 0.090 |
Why?
|
| Risk | 1 | 2012 | 747 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 463 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2011 | 234 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2010 | 120 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 419 | 0.080 |
Why?
|
| Sexuality | 1 | 2009 | 15 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1146 | 0.080 |
Why?
|
| Mice | 2 | 2017 | 17557 | 0.080 |
Why?
|
| Program Development | 1 | 2010 | 187 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 596 | 0.080 |
Why?
|
| Patient Safety | 1 | 2014 | 397 | 0.080 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 5 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 204 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2012 | 1473 | 0.080 |
Why?
|
| Age Factors | 4 | 2019 | 2808 | 0.080 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 624 | 0.080 |
Why?
|
| Veins | 1 | 2009 | 106 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3384 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2010 | 348 | 0.070 |
Why?
|
| Laparoscopy | 2 | 2013 | 501 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 403 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2010 | 1245 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 225 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4300 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 1262 | 0.070 |
Why?
|
| International Cooperation | 2 | 2017 | 157 | 0.070 |
Why?
|
| Masturbation | 1 | 2025 | 2 | 0.060 |
Why?
|
| Constriction | 1 | 2025 | 49 | 0.060 |
Why?
|
| Recurrence | 2 | 2009 | 1419 | 0.060 |
Why?
|
| Urothelium | 1 | 2004 | 60 | 0.060 |
Why?
|
| Retreatment | 1 | 2004 | 88 | 0.060 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2015 | 197 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 570 | 0.060 |
Why?
|
| Transdermal Patch | 1 | 2023 | 8 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 2861 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2022 | 37 | 0.050 |
Why?
|
| Testosterone Congeners | 1 | 2022 | 15 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2022 | 26 | 0.050 |
Why?
|
| Monitoring, Ambulatory | 1 | 2021 | 54 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 159 | 0.050 |
Why?
|
| HIV Infections | 1 | 2013 | 1860 | 0.050 |
Why?
|
| SEER Program | 1 | 2021 | 194 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 288 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2018 | 88 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 68 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 149 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1211 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2017 | 40 | 0.040 |
Why?
|
| Survival Rate | 1 | 2022 | 2005 | 0.030 |
Why?
|
| Premature Ejaculation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Child | 3 | 2022 | 24262 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 290 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 136 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1304 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 1003 | 0.030 |
Why?
|
| Patient Participation | 1 | 2018 | 220 | 0.030 |
Why?
|
| Stroke | 1 | 2023 | 958 | 0.030 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2014 | 4 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 57 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 109 | 0.030 |
Why?
|
| Manometry | 1 | 2014 | 48 | 0.030 |
Why?
|
| Patient Admission | 1 | 2015 | 183 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2014 | 50 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 182 | 0.030 |
Why?
|
| Arteries | 1 | 2014 | 222 | 0.030 |
Why?
|
| Canada | 1 | 2013 | 293 | 0.030 |
Why?
|
| Kinetics | 1 | 2014 | 1317 | 0.030 |
Why?
|
| Robotics | 1 | 2013 | 106 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1084 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 41 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 701 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 683 | 0.020 |
Why?
|
| Affect | 1 | 2011 | 158 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 1601 | 0.020 |
Why?
|
| Ligation | 1 | 2009 | 134 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2539 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2009 | 178 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1598 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 329 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 604 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 822 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1124 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 2235 | 0.010 |
Why?
|